Hospital- and Ventilator-Associated Pneumonia — Adult

Key Points

• HAP and VAP require a new pulmonary process plus compatible clinical deterioration; a positive airway culture alone is not pneumonia.
• Use the local hospital or ICU antibiogram rather than a universal broad regimen.
• Prior IV antibiotics and unit resistance patterns are major determinants of MRSA and resistant gram-negative risk.
• Obtain respiratory cultures before antibiotics when feasible and use results to de-escalate.
• Avoid routine double antipseudomonal therapy when resistance risk is low.
• Seven days of active antibiotics is adequate for most patients who improve appropriately.
• Procalcitonin does not replace clinical judgment for starting therapy.
• Prevention includes ventilator liberation, aspiration-risk reduction, and avoiding unnecessary broad antibiotics.

Algorithm

1. Confirm a compatible new infiltrate and respiratory/infectious deterioration while assessing alternative diagnoses.
2. Obtain respiratory and blood cultures when indicated without delaying treatment in sepsis.
3. Review prior cultures, IV antibiotic exposure, local antibiogram, shock, and structural lung disease.
4. Start empiric antipseudomonal and S. aureus coverage appropriate to resistance risk; add MRSA or a second gram-negative agent only when indicated.
5. Reassess at 48 to 72 hours using cultures, oxygenation, fever, secretions, imaging trajectory, and alternative diagnoses.
6. De-escalate to targeted therapy or stop antibiotics if pneumonia is no longer supported.
7. Treat most improving cases for about 7 days and address empyema, abscess, obstruction, or device source separately.
8. Implement prevention measures and reassess readiness for ventilator liberation daily.

Clinical Synopsis & Reasoning

Suspect HAP or VAP when a hospitalized patient develops a new or progressive infiltrate with fever, purulent respiratory secretions, leukocytosis or leukopenia, and worsening oxygenation. These findings are nonspecific and overlap with atelectasis, aspiration pneumonitis, pulmonary edema, ARDS, pulmonary embolism, and alveolar hemorrhage. Obtain lower respiratory tract cultures before new antibiotics when this can be done without meaningful delay. Noninvasive endotracheal aspirates are generally acceptable for VAP; invasive quantitative bronchoscopy is not required routinely. Blood cultures are appropriate in severe illness and can identify extrapulmonary bacteremia. Procalcitonin should not be used alone to decide whether to start antibiotics when clinical suspicion is meaningful, although trends can support discontinuation in selected contexts. Review prior respiratory isolates and antibiotics from the preceding 90 days, length of hospitalization, unit antibiogram, structural lung disease, and septic shock because these factors affect resistant-pathogen probability. HAP is not synonymous with the retired health care-associated pneumonia category; community patients should not receive broad HAP/VAP therapy solely because of remote health care exposure.

Treatment Strategy & Disposition

For suspected VAP or severe HAP, select empiric coverage for Staphylococcus aureus and gram-negative bacilli including Pseudomonas, then decide whether MRSA coverage and dual antipseudomonal therapy are warranted by local resistance, septic shock, prior IV antibiotics, structural lung disease, or other validated risk. Vancomycin or linezolid are standard MRSA agents. Antipseudomonal beta-lactams include cefepime, piperacillin-tazobactam, meropenem, or another locally active agent. A second antipseudomonal from a different class can be added when resistance risk is high, but unnecessary dual therapy should be avoided. Once culture and susceptibility data are available, narrow to the least broad effective regimen. Seven days of effective therapy is adequate for most HAP/VAP when clinical response is appropriate, regardless of pathogen, with longer treatment reserved for slow response, abscess, empyema, immunocompromise, or another complication. Drain empyema and address infected devices or obstruction. Daily assessment for ventilator liberation, aspiration prevention, head-of-bed elevation, oral care, and minimizing unnecessary sedation are part of VAP prevention.

Epidemiology / Risk Factors

• HAP and VAP are important nosocomial infections associated with longer hospitalization, cost, and mortality.
• Ventilation, aspiration, impaired consciousness, prolonged hospitalization, prior antibiotics, and severe underlying illness increase risk.
• Pathogen distribution varies by hospital and unit, making local microbiology more important than generic lists.
• Multidrug-resistant gram-negative bacilli and MRSA are concentrated in patients with specific exposures rather than every hospital-acquired case.
• Prevention bundles have reduced VAP incidence in many ICUs.

Investigations

Common MDR Risk Factors

Pharmacology

Prognosis / Complications

• Mortality reflects both pneumonia severity and the patient's underlying critical illness.
• Delayed inactive empiric therapy in septic shock can worsen outcome, while unnecessary broad therapy increases drug toxicity and resistance.
• Clinical improvement should appear through oxygenation, fever, hemodynamics, and secretion burden before chest imaging fully clears.
• Empyema, necrotizing pneumonia, abscess, and bacteremia prolong recovery and may require source control.
• Recurrent VAP risk persists while invasive ventilation and aspiration risk continue.

Patient Education / Counseling

• Explain to families that airway cultures can contain colonizing bacteria and that antibiotics may be narrowed or stopped as results clarify the diagnosis.
• When patients recover, review aspiration prevention, oral care, mobility, and smoking cessation where relevant.
• Patients discharged on antibiotics should understand the exact stop date rather than assuming treatment continues until the radiograph is normal.
• Seek reassessment for recurrent fever, worsening breathlessness, confusion, or reduced oxygenation after discharge.
• For patients with repeated resistant infections, document prior organisms clearly because those cultures can guide safer future empiric therapy.

Notes

HAP and VAP are stewardship-intensive diagnoses. The goal is not to start the broadest possible antibiotics in every hospitalized patient with an infiltrate. The goal is to give active initial therapy to the patient who truly has nosocomial pneumonia, using that patient's prior cultures and the local antibiogram, then remove unnecessary coverage quickly. A seven-day course is usually enough when therapy is active and the patient improves. The same discipline that prevents undertreatment of septic shock also prevents resistance, kidney injury, and C. difficile from prolonged broad therapy.

References

1. ATS/IDSA Clinical Practice Guidelines for HAP and VAP — Link